• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
    • Corporate Videos
  • Development Programs
    • Biopharmaceutical Trials
    • Group Strategy and Target Markets
    • NTI164
    • Clinical Trials
    • Pathways to Commercialisation
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Investor Conference Calls  
    • Company Reports
    • Presentations
    • Research
    • News & Media
    • Fact Sheets
    • Analyst Reports
    • Right to Receive Documents
  • Contact

Research

19 September 2022 RaaS Advisory: Targeting treatment for autism spectrum disorder
20 July 2022 Bioshares – Edition 921: Neurotech International – Positive Study Results
3 June 2022 Bioshares – Edition 918: Neurotech International – Efficacy Results Pending

Footer

Suite 102 / Level 1, 55 Collins Street
Melbourne VIC 3000
Australia

moc.l1775535127anoit1775535127anret1775535127nihce1775535127torue1775535127n@ofn1775535127i1775535127

+61 (3) 9498 3132

Subscribe to our latest announcements

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2026 Neurotech International • Site by White Noise Communications

Download prospectus